Transcatheter Mitral Valve Implantation (TMVI) Using Edwards SAPIEN 3 Prostheses in Patients at Very High or Prohibitive Surgical Risk: A Single-Center Experience

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Number of procedures (total)</td><td class="align_center">7</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Access for TMVI</td><td class="align_left"> </td></tr><tr><td class="align_left"> Transseptal/transvenous</td><td class="align_center">100% (7/7)</td></tr><tr><td class="align_left"> Transapical</td><td class="align_center">0% (0/7)</td></tr><tr><td class="align_left"> Transatrial</td><td class="align_center">0% (0/7)</td></tr><tr><td class="align_left">Complete technical procedural success (according to MVARC)</td><td class="align_center">100% (7/7)</td></tr><tr><td class="align_left">Periprocedural death (within 24 hours)</td><td class="align_center">0% (0/7)</td></tr><tr><td class="align_left">Procedural duration (minutes, median, IQR)</td><td class="align_center">60 (60; 83)</td></tr><tr><td class="align_left">Fluoroscopy time (minutes, median, IQR)</td><td class="align_center">11 (10; 15)</td></tr><tr><td class="align_left">Area dose product (cGy ∗ cm<sup>2</sup>, median, IQR)</td><td class="align_center">4934 (3349; 8417)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Journal of Interventional Cardiology

tab2

Table 2

Table 2: Transcatheter Mitral Valve Implantation (TMVI) Using Edwards SAPIEN 3 Prostheses in Patients at Very High or Prohibitive Surgical Risk: A Single-Center Experience 

Table 2 | Transcatheter Mitral Valve Implantation (TMVI) Using Edwards SAPIEN 3 Prostheses in Patients at Very High or Prohibitive Surgical Risk: A Single-Center Experience 